EP1397489A4 - Agents toxiques, riboyzmes, andyzmes et oligonucleotides antisens specifiques des tissus et des pathogenes et procede d'utilisation associe - Google Patents

Agents toxiques, riboyzmes, andyzmes et oligonucleotides antisens specifiques des tissus et des pathogenes et procede d'utilisation associe

Info

Publication number
EP1397489A4
EP1397489A4 EP01926973A EP01926973A EP1397489A4 EP 1397489 A4 EP1397489 A4 EP 1397489A4 EP 01926973 A EP01926973 A EP 01926973A EP 01926973 A EP01926973 A EP 01926973A EP 1397489 A4 EP1397489 A4 EP 1397489A4
Authority
EP
European Patent Office
Prior art keywords
riboyzms
andyzames
pathogens
tissues
antisense oligonucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01926973A
Other languages
German (de)
English (en)
Other versions
EP1397489A2 (fr
Inventor
James S Norris
Gary A Clawson
Caroline Westwater
David Schofield
Michael G Schmidt
Brian Hoel
Joseph Dolan
Wei-Hua Pan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of South Carolina
Medical University of South Carolina MUSC
Penn State Research Foundation
Original Assignee
University of South Carolina
Medical University of South Carolina MUSC
Penn State Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of South Carolina, Medical University of South Carolina MUSC, Penn State Research Foundation filed Critical University of South Carolina
Priority to EP06001413A priority Critical patent/EP1702983A3/fr
Publication of EP1397489A2 publication Critical patent/EP1397489A2/fr
Publication of EP1397489A4 publication Critical patent/EP1397489A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
EP01926973A 2000-04-13 2001-04-13 Agents toxiques, riboyzmes, andyzmes et oligonucleotides antisens specifiques des tissus et des pathogenes et procede d'utilisation associe Withdrawn EP1397489A4 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06001413A EP1702983A3 (fr) 2000-04-13 2001-04-13 Agents toxiques, ribozymes, ADNzymes et oligonucléotides antisens spécifiques des tissus et des pathogènes et procédé d'utilisation associé

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US54844900A 2000-04-13 2000-04-13
US548449 2000-04-13
US25181000P 2000-12-07 2000-12-07
US251810P 2000-12-07
PCT/US2001/012130 WO2001079524A2 (fr) 2000-04-13 2001-04-13 Agents toxiques, riboyzmes, andyzmes et oligonulceotides antisens specifiques des tissus et des pathogenes et procede d'utilisation associe

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP06001413A Division EP1702983A3 (fr) 2000-04-13 2001-04-13 Agents toxiques, ribozymes, ADNzymes et oligonucléotides antisens spécifiques des tissus et des pathogènes et procédé d'utilisation associé

Publications (2)

Publication Number Publication Date
EP1397489A2 EP1397489A2 (fr) 2004-03-17
EP1397489A4 true EP1397489A4 (fr) 2005-05-11

Family

ID=26941841

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01926973A Withdrawn EP1397489A4 (fr) 2000-04-13 2001-04-13 Agents toxiques, riboyzmes, andyzmes et oligonucleotides antisens specifiques des tissus et des pathogenes et procede d'utilisation associe

Country Status (5)

Country Link
EP (1) EP1397489A4 (fr)
JP (1) JP2004525602A (fr)
AU (2) AU2001253471B2 (fr)
CA (1) CA2406403A1 (fr)
WO (1) WO2001079524A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2365901A1 (fr) 1999-04-14 2000-10-19 Musc Foundation For Research Development Agents toxiques et ribozymes specifiques de tissu et specifiques de pathogene
EP2298869A1 (fr) * 2003-06-13 2011-03-23 University Of Medicine And Dentistry Of New Jersey Production des protéines recombinantes en présence d'ARNm interférase
EP1677834B1 (fr) * 2003-10-06 2014-01-08 Gangagen, Inc. Phage therapeutique dose de maniere definie
SG11201604198YA (en) 2013-12-30 2016-07-28 Curevac Ag Methods for rna analysis
WO2019171191A1 (fr) * 2018-03-05 2019-09-12 Dr. Reddy's Institute Of Life Sciences Modèles de poisson zèbre embryonnaires utilisant un knock-down médié par dnazymes
CN118340133A (zh) * 2024-04-24 2024-07-16 农业农村部环境保护科研监测所 一种高效削减牛粪抗生素耐药基因的生态技术方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991008312A1 (fr) * 1989-12-01 1991-06-13 Gene-Trak Systems Detection des transcriptions du vph
WO1993023569A1 (fr) * 1992-05-11 1993-11-25 Ribozyme Pharmaceuticals, Inc. Procede et reactif d'inhibition de la replication virale
WO1994026934A2 (fr) * 1993-05-06 1994-11-24 Baxter Diagnostics Inc. Methode de detection du papillomavirus chez l'homme
WO1997003211A1 (fr) * 1995-07-13 1997-01-30 Isis Pharmaceuticals, Inc. Inhibition antisens de la replication du virus de l'hepatite b
WO2000009673A1 (fr) * 1998-08-13 2000-02-24 Johnson & Johnson Research Pty. Limited Dnazymes et methodes de traitement de troubles en rapport avec le papillomavirus
WO2002046449A2 (fr) * 2000-12-07 2002-06-13 The Penn State Research Foundation Selection d'acides nucleiques catalytiques cibles sur des agents infectieux

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9015845D0 (en) * 1990-07-19 1990-09-05 Emery Vincent C Diagnostic method
FR2679254B1 (fr) * 1991-07-17 1993-11-19 Clonatec Sondes oligonucleotidiques pour le typage et la detection des papillomavirus humains.
US5767259A (en) * 1994-12-27 1998-06-16 Naxcor Oligonucleotides containing base-free linking groups with photoactivatable side chains
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US5989804A (en) * 1994-07-08 1999-11-23 New England Medical Center Hospitals, Inc. E6 binding proteins

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991008312A1 (fr) * 1989-12-01 1991-06-13 Gene-Trak Systems Detection des transcriptions du vph
WO1993023569A1 (fr) * 1992-05-11 1993-11-25 Ribozyme Pharmaceuticals, Inc. Procede et reactif d'inhibition de la replication virale
WO1994026934A2 (fr) * 1993-05-06 1994-11-24 Baxter Diagnostics Inc. Methode de detection du papillomavirus chez l'homme
WO1997003211A1 (fr) * 1995-07-13 1997-01-30 Isis Pharmaceuticals, Inc. Inhibition antisens de la replication du virus de l'hepatite b
WO2000009673A1 (fr) * 1998-08-13 2000-02-24 Johnson & Johnson Research Pty. Limited Dnazymes et methodes de traitement de troubles en rapport avec le papillomavirus
WO2002046449A2 (fr) * 2000-12-07 2002-06-13 The Penn State Research Foundation Selection d'acides nucleiques catalytiques cibles sur des agents infectieux

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
ALVAREZ-SALAS L M ET AL: "Inhibition of HPV-16 E6/E7 immortalization of normal keratinocytes by hairpin ribozymes.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 3 FEB 1998, vol. 95, no. 3, 3 February 1998 (1998-02-03), pages 1189 - 1194, XP002317756, ISSN: 0027-8424 *
CHEN Z ET AL: "EFFECTIVENESS OF THREE RIBOZYMES FOR CLEAVAGE OF AN RNA TRANSCRIPT FROM HUMAN PAPILLOMAVIRUS TYPE 18", CANCER GENE THERAPY, NORWALK, CT, US, vol. 2, no. 4, 1995, pages 263 - 271, XP008040034, ISSN: 0929-1903 *
DIAZ-FLORES ESTEVEZ F ET AL: "Detection of human Papillomavirus types 6b, 11, 16 and 18 in cervical scrapes by a multiplex polymerase chain reaction", REVISTA DE LA SOCIEDAD ESPANOLA DE QUIMICA CLINICA 1996 SPAIN, vol. 15, no. 6, 1996, pages 420 - 424, XP001203827, ISSN: 0213-8514 *
JI W ET AL: "Inhibition of hepatitis B virus by retroviral vectors expressing antisense RNA.", JOURNAL OF VIRAL HEPATITIS. MAY 1997, vol. 4, no. 3, May 1997 (1997-05-01), pages 167 - 173, XP002317755, ISSN: 1352-0504 *
PAN WEI-HUA ET AL: "A selection system for identifying accessible sites in target RNAs", RNA (NEW YORK), vol. 7, no. 4, April 2001 (2001-04-01), pages 610 - 621, XP002317752, ISSN: 1355-8382 *
PASSMAN M ET AL: "In situ demonstration of inhibitory effects of hammerhead ribozymes that are targeted to the hepatitis Bx sequence in cultured cells.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 24 FEB 2000, vol. 268, no. 3, 24 February 2000 (2000-02-24), pages 728 - 733, XP002317754, ISSN: 0006-291X *
PLOURDE ROBERT ET AL: "Targeted therapy for viral hepatitis", ADVANCED DRUG DELIVERY REVIEWS, vol. 17, no. 3, 1995, pages 311 - 315, XP002317757, ISSN: 0169-409X *
See also references of WO0179524A3 *
STEELE C ET AL: "EFFECTS OF HUMAN PAPILLOMAVIRUS TYPE 18-SPECIFIC ANTISENSE OLIGONUCLEOTIDES ON THE TRANSFORMED PHENOTYPE OF HUMAN CARCINOMA CELL LINES", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 53, no. 10, 15 May 1993 (1993-05-15), pages 2330 - 2337, XP002030937, ISSN: 0008-5472 *
VENTURINI FRANCESCA ET AL: "Kinetic selection of HPV 16 E6/E7-directed antisense nucleic acids: Anti-proliferative effects on HPV 16-transformed cells", NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 27, no. 7, 1 April 1999 (1999-04-01), pages 1585 - 1592, XP002234550, ISSN: 0305-1048 *
WEIZSAECKER VON F ET AL: "CLEAVAGE OF HEPATITIS B VIRUS RNA BY THREE RIBOZYMES TRANSCRIBED FROM A SINGLE DNA TEMPLATE", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 189, no. 2, 15 December 1992 (1992-12-15), pages 743 - 748, XP000652045, ISSN: 0006-291X *
WELCH P J ET AL: "Intracellular application of hairpin ribozyme genes against hepatitis B virus.", GENE THERAPY. JUL 1997, vol. 4, no. 7, July 1997 (1997-07-01), pages 736 - 743, XP002317753, ISSN: 0969-7128 *

Also Published As

Publication number Publication date
AU5347101A (en) 2001-10-30
EP1397489A2 (fr) 2004-03-17
WO2001079524A2 (fr) 2001-10-25
CA2406403A1 (fr) 2001-10-25
AU2001253471B2 (en) 2007-07-26
JP2004525602A (ja) 2004-08-26
WO2001079524A3 (fr) 2004-01-08

Similar Documents

Publication Publication Date Title
EP1294410A4 (fr) Procede et composition de nettoyage d'instruments medicaux
EE200300074A (et) BCL-2 antisenss-oligonukleotiidi kasutamine ja farmatseutiline kompositsioon
ATE374643T1 (de) Verminderung des haarwuchses
HUP0301049A3 (en) Personal cleansing bar and preparation process
DE60115874D1 (de) Instrument zur chirurgischen behandlung
IL145145A0 (en) Single operator exchange catheters and methods of use
EP1539778A4 (fr) Deprotection et purification d'oligonucleotides et de leurs derives
HUP0302585A3 (en) Lactic acid bacteria capable of reducing an individual's tendency to develop allerreactions
AU5464601A (en) Treatment of scale
ATE232378T1 (de) Reinigungspflaster zur verbesserung des hautzustandes
HUP0102698A3 (en) Use of growth hormone secretagogues for treatment of physical performance decline
EP1252173A4 (fr) Purification d'oligonucl otides
EP1397489A4 (fr) Agents toxiques, riboyzmes, andyzmes et oligonucleotides antisens specifiques des tissus et des pathogenes et procede d'utilisation associe
EP1505871A4 (fr) Conservation d'arn et de la morphologie dans des cellules et dans des tissus
DE59912497D1 (de) Haarbehandlungsmittel enthaltend Oligoester
DE60105053D1 (de) Zusammensetzungen zur behandlung von gewebe
ITUD20000172A0 (it) Dispositivo e procedimento per l'igienizzazione di calzature
DE60125035D1 (de) Behandlung von plasmid-haltigen lösungen
IS6626A (is) Kristallskenndur meðferðarmiðill
GB0012401D0 (en) Treatment of infection in animals
GB0022210D0 (en) Treatment of infection in animals
UA4888S (uk) Комплект етикеток для солодкої настойки «поліський букет»
FR2794622B1 (fr) Procede d'epilation
ATE285468T1 (de) Gewebehandlungszubereitung
EP1158991A4 (fr) Traitement de l'asthme

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20021113

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 12N 15/11 A

Ipc: 7C 12N 15/74 B

A4 Supplementary search report drawn up and despatched

Effective date: 20050321

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060125